Immunoglobulins Market Report
Immunoglobulins Market, By Product (IgG, IgA, IgM, IgE, IgD), By Mode of Delivery (Intravenous, Subcutaneous), By Application (Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP), Immunodeficiency Disease, Myasthenia Gravis, Others) and Region - COVID-19 Impact Analysis and Forecast to 2026.
This market research report provides in-depth information on trends, dynamics, revenue opportunities, competitive landscape, and recent developments in the global immunoglobulins market. The historic years considered for the study are 2016-2019, the base year is 2020, the estimated year is 2021, and the forecast period is 2022-2026.
Immunoglobulins Market, By Product (IgG, IgA, IgM, IgE, IgD), By Mode of Delivery (Intravenous, Subcutaneous), By Application (Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP), Immunodeficiency Disease, Myasthenia Gravis, Others) and Region ...
Impact of COVID-19 on Immunoglobulins Market
Covid-19 has impacted the market dynamics, competition, and global supply chain. The revenues have gone down in 2020 and may resume an uptrend gradually from 2021. Companies optimizing their operation and strategy will sustain and beat the competition.
Note: The summary below might not have included insights on covid impact since we have large number of reports.
The Immunoglobulins Market is estimated to grow from USD 11.7 billion in 2020 to USD 16.8 billion by 2026 at a healthy CAGR of 6.3% during the forecast period.
Immunoglobulin, also referred to as an antibody, may be a protein synthesized by plasma cells and other lymphocytes. It's a posh entity that exerts its immunomodulatory effect on different components of the system. It's obtained from the blood via the method of fractionation and is purified for therapeutic and non-therapeutic applications.
Key players operating in the immunoglobulins market are-
The rise in the geriatric population & the number of hemophilic patients improved immunoglobulin production due to the emergence of advanced technologies, and enhanced purification techniques, with better plasma yield, are some of the key factors bolstering the market growth. Also, the surge in prevalence of diseases such as chronic inflammatory demyelinating polyneuropathy (CIDP), hypogammaglobulinemia & others is likely to augment the industry growth. However, stringent government regulations about immunoglobulin products and the high risk of side effects due to the usage of immunoglobulin are anticipated to hinder the market growth.
Based on application, the market has been classified into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency disease, myasthenia gravis, and others. The hypogammaglobulinemia segment accounted for the largest market share in 2020. This is ascribed to the substantial rise in the prevalence of hypogammaglobulinemia disorder around the world over the years. For instance, hypogammaglobulinemia is the most common chronic immune defect in patients with lymphoproliferative disorders (LPDs). Its prevalence rate is ~2 per 100,000 population yearly, worldwide, which further boosts the segment growth.
The market in North America accounted for the largest share in 2020 and is projected to continue its dominance during the review period. This is mainly attributed to increasing healthcare expenditure, the growing inclination of clinicians towards immunodeficiency therapies, and the rising level of consciousness for the products involved in the treatment of immunodeficiency disorders. Moreover, beneficial government initiatives and a rise in the number of research partnerships further proliferate regional growth.
The COVID-19 outbreak positively influenced the growth of the Immunoglobulins market. The growing use of immunoglobulin in the treatment of COVID-19 infection can be effective in the management of the disease. In the US, the impact of COVID-19 on the immunoglobulin market is robust as there have been increasing research studies on immunoglobulins as an effective therapy in the treatment of COVID-19. For instance, as per the National Clinical Trial (NCT) Registry, as of 9th March 2021, in the US, there was around 50 immunoglobulin based ongoing clinical trials across different phases of development which shows a positive impact on the market as this can result to the development of new effective therapy for COVID-19 in the coming years.
Here is the list of the group of customers that the immunoglobulins market hopes to have the greatest opportunity to convert-
Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at firstname.lastname@example.org.
The immunoglobulins market is expected to witness an impressive growth of 6.3% CAGR in the coming years.
Baxter international Inc. (US), CSL Ltd. (Australia), Grifols S.A (Spain), Octapharma AG (Switzer-land), Kedrion Biopharma Inc. (US), LFB group (France), Biotest AG (Germany), China Biologics Products, Inc. (China), Shire (Baxalta) (US), and Bayer Healthcare (Germany) are among the key players in the immunoglobulins market.
The immunoglobulins market size is expected to reach USD 16.8 billion in the foreseeable future.
The hypogammaglobulinemia segment accounted for the largest share in the immunoglobulins market in 2020.
North America is expected to remain dominant in the immunoglobulins market in the next five years.
Immunoglobulins distributors, Immunoglobulins suppliers, Immunoglobulins manufacturers, Hospitals, Government bodies are the target audience in the immunoglobulins market.